Eltrombopag Olamine
Eltrombopag Olamine · Targeted Oncology Agent
Indications & Uses
Approved for use in oncology care according to FDA-approved indications.
Contraindications
Hypersensitivity to active ingredient or any formulation excipients.
Side Effects & Warnings
Fatigue, nausea, diarrhea, hematologic laboratory abnormalities, and decreased appetite.
Drug & Dietary Interactions
Caution with strong CYP3A inhibitors or inducers; review concurrent medications.
For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.
Patient & Caregiver Support
Ask About This Medication
Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.